- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL)
CUSIP: 55083R104
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 19,277,111
- Total 13F shares
- 152,354,676
- Share change
- +2,155,197
- Total reported value
- $81,758,597
- Put/Call ratio
- 207%
- Price per share
- $0.54
- Number of holders
- 111
- Value change
- +$815,972
- Number of buys
- 37
- Number of sells
- 40
Quarterly Holders Quick Answers
What is CUSIP 55083R104?
CUSIP 55083R104 identifies LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 55083R104:
Top shareholders of LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Robert Nelsen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
36,542,716
mixed-class rows
|
$83,020,992 | — | 14 Jun 2024 | |
| GSK plc |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| ARCH Venture Fund IX, L.P. |
13D/G
|
Robert Nelsen |
13%
|
36,597,716
|
$17,200,927 | $0 | 31 Dec 2024 | |
| MWG Management Ltd. |
13F
|
Company |
105%
|
20,162,332
|
$12,903,892 | — | 31 Dec 2024 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
9.2%
|
27,161,892
|
$12,766,089 | +$3,611,010 | 31 Mar 2025 | |
| Hans Edgar Bishop |
3/4/5
|
Director |
—
mixed-class rows
|
4,815,614
mixed-class rows
|
$10,683,200 | — | 14 Jun 2024 | |
| Orland Properties Ltd |
13F
|
Company |
78%
|
15,093,969
|
$9,660,140 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
4.5%
from 13D/G
|
13,265,869
|
$8,490,156 | — | 31 Dec 2024 | |
| Decheng Capital LLC |
13F
|
Company |
62%
|
11,909,341
|
$7,621,978 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
51%
|
9,766,083
|
$6,250,292 | — | 31 Dec 2024 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
43%
|
8,325,000
|
$5,328,000 | — | 31 Dec 2024 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
42%
|
8,133,047
|
$5,205,150 | — | 31 Dec 2024 | |
| venBio Partners LLC |
13F
|
Company |
37%
|
7,102,190
|
$4,545,402 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
36%
|
6,910,749
|
$4,424,000 | — | 31 Dec 2024 | |
| Alphabet Inc. |
13F
|
Company |
30%
|
5,865,125
|
$3,753,680 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
21%
|
4,137,264
|
$2,648,473 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
19%
|
3,748,673
|
$2,399,151 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
19%
|
3,754,745
|
$2,315,197 | — | 31 Dec 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
16%
|
3,103,623
|
$1,986,319 | — | 31 Dec 2024 | |
| HSG Holding Ltd |
13F
|
Company |
16%
|
3,045,997
|
$1,736,218 | — | 31 Dec 2024 | |
| MIC Capital Management UK LLP |
13F
|
Company |
9%
|
1,740,569
|
$1,113,964 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
8.5%
|
1,645,787
|
$1,053,304 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
8.4%
|
1,612,146
|
$1,031,773 | — | 31 Dec 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
7.2%
|
1,385,301
|
$886,593 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
6.8%
|
1,310,224
|
$838,543 | — | 31 Dec 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
6.6%
|
1,276,037
|
$816,664 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
6.3%
|
1,214,287
|
$777,143 | — | 31 Dec 2024 | |
| Almitas Capital LLC |
13F
|
Company |
5.4%
|
1,050,520
|
$672,333 | — | 31 Dec 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
5.2%
|
1,004,642
|
$642,971 | — | 31 Dec 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
5%
|
966,265
|
$618,410 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
5%
|
957,507
|
$612,804 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
4.5%
|
864,287
|
$553,143 | — | 31 Dec 2024 | |
| JOHNSON & JOHNSON |
13F
|
Company |
4.3%
|
823,317
|
$526,923 | — | 31 Dec 2024 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
|
Company |
4.3%
|
823,317
|
$526,923 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
3.3%
|
641,173
|
$410,350 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
3.3%
|
627,321
|
$401,486 | — | 31 Dec 2024 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
3.1%
|
588,235
|
$376,470 | — | 31 Dec 2024 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
2.9%
|
551,851
|
$353,185 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
2.7%
|
525,782
|
$336,501 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.2%
|
433,265
|
$277,290 | — | 31 Dec 2024 | |
| Invesco Ltd. |
13F
|
Company |
2.1%
|
407,205
|
$260,611 | — | 31 Dec 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
406,234
|
$259,990 | — | 31 Dec 2024 | |
| Clarius Group, LLC |
13F
|
Company |
2.1%
|
399,168
|
$255,468 | — | 31 Dec 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
1.6%
|
308,551
|
$197,473 | — | 31 Dec 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.6%
|
306,400
|
$196,096 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
1.5%
|
281,129
|
$179,913 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
1.3%
|
258,380
|
$165,362 | — | 31 Dec 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
1.3%
|
253,669
|
$162,348 | — | 31 Dec 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
1.2%
|
239,439
|
$153,241 | — | 31 Dec 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.1%
|
220,790
|
$141,306 | — | 31 Dec 2024 |
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q1 2025
As of 31 Mar 2025,
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) was held by
111 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
152,354,676 shares.
The largest 10 holders included
MWG Management Ltd., Foresite Capital Management IV, LLC, Orland Properties Ltd, BlackRock, Inc., Decheng Capital LLC, VANGUARD GROUP INC, Foresite Capital Management V, LLC, venBio Partners LLC, PRICE T ROWE ASSOCIATES INC /MD/, and Alphabet Inc..
This page lists
110
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
101
Q1 2025 holders
111
Holder diff
10
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.